LIXTE Biotechnology Holdings is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The summit brings together leaders in health, culture, science, and community to advance health equity for Black men and families, inspired by the music, legacy, and lived experiences of De La Soul.
The event is rooted in De La Soul's song "Good Health," written following the passing of founding member David Jolicoeur, and reflects the group's evolution from musical pioneers to wellness advocates. Developed in collaboration with Blacksmith Holdings, the program will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness.
LIXTE stated the summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA. The company aims to create a space connecting scientific innovation with communities most impacted by health disparities. LIXTE has demonstrated that its lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity.
Based on extensive published preclinical data available at www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound represents a pioneering effort in an entirely new field of cancer biology called activation lethality, advancing a new treatment paradigm covered by a comprehensive patent portfolio.
Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. This sponsorship represents a significant intersection of pharmaceutical innovation and community health initiatives, particularly important given the documented health disparities affecting Black communities in areas including cancer outcomes, cardiovascular disease, and mental health access.
The summit's focus on multiple dimensions of wellness—from physical conditions like cancer and heart disease to mental health and relational wellbeing—addresses the comprehensive nature of health disparities that cannot be solved through medical interventions alone. By bringing together scientific experts with community leaders and cultural influencers, the event creates a unique platform for dialogue that could inform both research priorities and community health strategies.
For LIXTE, this represents an opportunity to demonstrate how pharmaceutical innovation can be integrated with community-centered approaches to health equity. The company's research into activation lethality and PP2A inhibition represents a novel approach to cancer treatment that could potentially benefit populations disproportionately affected by certain cancers. More information about the full press release is available at https://ibn.fm/0kkqK.
